CA2518398A1 - Heterocyclic kinase inhibitors: methods of use and synthesis - Google Patents

Heterocyclic kinase inhibitors: methods of use and synthesis Download PDF

Info

Publication number
CA2518398A1
CA2518398A1 CA002518398A CA2518398A CA2518398A1 CA 2518398 A1 CA2518398 A1 CA 2518398A1 CA 002518398 A CA002518398 A CA 002518398A CA 2518398 A CA2518398 A CA 2518398A CA 2518398 A1 CA2518398 A1 CA 2518398A1
Authority
CA
Canada
Prior art keywords
alkyl
independently
heterocyclyl
heteroaryl
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002518398A
Other languages
English (en)
French (fr)
Inventor
M. Arshad Siddiqui
David Belanger
Chaoyang Dai
Lianyun Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2518398A1 publication Critical patent/CA2518398A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002518398A 2003-03-10 2004-03-10 Heterocyclic kinase inhibitors: methods of use and synthesis Abandoned CA2518398A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US45345703P 2003-03-10 2003-03-10
US60/453,457 2003-03-10
US46091003P 2003-04-07 2003-04-07
US60/460,910 2003-04-07
US46302503P 2003-04-15 2003-04-15
US60/463,025 2003-04-15
US50271003P 2003-09-12 2003-09-12
US60/502,710 2003-09-12
PCT/US2004/007286 WO2004080463A1 (en) 2003-03-10 2004-03-10 Heterocyclic kinase inhibitors: methods of use and synthesis

Publications (1)

Publication Number Publication Date
CA2518398A1 true CA2518398A1 (en) 2004-09-23

Family

ID=32996376

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002518398A Abandoned CA2518398A1 (en) 2003-03-10 2004-03-10 Heterocyclic kinase inhibitors: methods of use and synthesis

Country Status (5)

Country Link
EP (1) EP1601357A4 (enExample)
JP (1) JP2006519846A (enExample)
CA (1) CA2518398A1 (enExample)
MX (1) MXPA05009722A (enExample)
WO (1) WO2004080463A1 (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
KR20080000665A (ko) 2005-04-22 2008-01-02 알란토스 파마슈티컬즈 홀딩, 인코포레이티드 디펩티딜 펩티다아제-ⅳ 억제제
JP4976394B2 (ja) * 2005-08-17 2012-07-18 シェーリング コーポレイション 新規な高親和性のキノリンベースのキナーゼリガンド
EP3719018B1 (en) 2006-04-25 2025-08-27 Astex Therapeutics Ltd Purine and deazapurine derivatives as pharmaceutical compounds
US7511063B2 (en) * 2006-08-16 2009-03-31 Schering Corporation High affinity quinoline-based kinase ligands
WO2008059370A2 (en) 2006-11-17 2008-05-22 Pfizer Japan Inc. Substituted bicyclocarboxyamide compounds
DE602007008469D1 (de) 2006-12-07 2010-09-23 Hoffmann La Roche 2-aminochinoline als 5-ht(5a)-rezeptorantagonisten
JP5671236B2 (ja) 2007-03-14 2015-02-18 ランバクシー ラボラトリーズ リミテッド ホスホジエステラーゼ阻害剤としてのピラゾロ（３，４−ｂ）ピリジン誘導体
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
WO2008150364A1 (en) * 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
US8614326B2 (en) * 2007-08-22 2013-12-24 Allergan, Inc. Therapeutic quinoline and naphthalene derivatives
AU2008303602A1 (en) * 2007-09-27 2009-04-02 F. Hoffmann-La Roche Ag Quinoline derivatives as 5HT5A receptor antagonists
NZ585261A (en) 2007-10-11 2011-10-28 Astrazeneca Ab Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors
WO2009051112A1 (ja) 2007-10-15 2009-04-23 Takeda Pharmaceutical Company Limited アミド化合物およびその用途
EP2215089B1 (en) 2007-11-02 2012-06-27 Vertex Pharmaceuticals Incorporated [1h- pyrazolo [3, 4-b]pyridine-4-yl]-phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
WO2009095752A1 (en) * 2008-01-29 2009-08-06 Glenmark Pharmaceuticals, S.A. Fused pyrazole derivatives as cannabinoid receptor modulators
CN101959876A (zh) * 2008-03-05 2011-01-26 弗·哈夫曼-拉罗切有限公司 2-氨基喹啉类化合物
BRPI0909824A2 (pt) * 2008-03-07 2019-03-06 F. Hoffmann-La Roche Ag 2-aminoquinolinas
AU2009221389A1 (en) * 2008-03-07 2009-09-11 F. Hoffmann-La Roche Ag 2-Aminoquinoline derivatives
WO2009112395A1 (en) 2008-03-12 2009-09-17 F. Hoffmann-La Roche Ag 2-aminoquinolines as 5-ht5a receptor antagonists
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
PL2401267T3 (pl) 2009-02-27 2014-06-30 Ambit Biosciences Corp Pochodne chinazoliny modulujące kinazę JAK i ich zastosowanie w metodach
WO2010101949A1 (en) * 2009-03-02 2010-09-10 Sirtris Pharmaceuticals, Inc. 8-substituted quinolines and related analogs as sirtuin modulators
HRP20230248T1 (hr) * 2009-06-12 2023-04-14 Abivax Spojevi korisni za liječenje preranog starenja, te naročito progerije
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
SG181719A1 (en) 2009-12-17 2012-07-30 Schering Corp Quinoline amide m1 receptor positive allosteric modulators
BR112012018865A2 (pt) 2010-01-29 2016-04-12 Boehringer Ingelheim Int naftiridinas substituídas e seu uso como inibidores de quinase syk
US8815902B2 (en) 2010-06-15 2014-08-26 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide M1 receptor positive allosteric modulators
CA2805932A1 (en) * 2010-08-27 2012-03-01 Gruenenthal Gmbh Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators
CN103298805A (zh) 2010-09-01 2013-09-11 埃姆比特生物科学公司 喹唑啉化合物及其使用方法
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
WO2012122370A2 (en) 2011-03-08 2012-09-13 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
ME03589B (me) 2011-04-01 2020-07-20 Astrazeneca Ab Terapeutski tretman
MX2013013090A (es) 2011-05-10 2013-12-16 Merck Sharp & Dohme Aminopirimidinas como inhibidores de tirosina cinaza del bazo.
JP2014513687A (ja) 2011-05-10 2014-06-05 メルク・シャープ・アンド・ドーム・コーポレーション Ｓｙｋ阻害薬としてのピリジルアミノピリジン
EP2706852B1 (en) 2011-05-10 2018-08-22 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
JP5860960B2 (ja) 2011-07-26 2016-02-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換キノリン類及び医薬としてのそれらの使用
EP2763976B1 (en) 2011-10-05 2016-05-18 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
EP2763974B1 (en) 2011-10-05 2016-09-14 Merck Sharp & Dohme Corp. Phenyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
WO2013052393A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
PT2785349T (pt) 2011-11-30 2019-12-11 Astrazeneca Ab Tratamento combinado de cancro
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
WO2013192128A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
WO2013192423A2 (en) 2012-06-20 2013-12-27 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
WO2013192125A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as syk inhibitors
EP2863916B1 (en) 2012-06-22 2018-07-18 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (syk) inhibitors
US9416111B2 (en) 2012-06-22 2016-08-16 Merck Sharp & Dohme Corp. Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors
WO2014031438A2 (en) 2012-08-20 2014-02-27 Merck Sharp & Dohme Corp. SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2900665B1 (en) 2012-09-28 2018-01-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
EP2922544B1 (en) 2012-11-21 2018-08-01 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
EP3063302B1 (en) 2013-10-30 2019-12-04 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
EP3083559B1 (en) 2013-12-20 2021-03-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9783531B2 (en) 2013-12-20 2017-10-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP3083560B1 (en) 2013-12-20 2021-10-27 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP3116506B1 (en) 2014-03-13 2019-04-17 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
PT3212629T (pt) * 2014-10-31 2019-02-04 Genoscience Pharma Sas Substituído 2,4 diamino-quinoline como novos agentes anti cancro
ES2849560T3 (es) * 2016-05-04 2021-08-19 Genoscience Pharma Sas Derivados de 2,4-diamino-quinolina sustituidos para su uso en el tratamiento de enfermedades proliferativas
AU2018286247B2 (en) * 2017-06-14 2021-12-23 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Syk inhibitor and use method therefor
WO2019023278A1 (en) * 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
EP3620164A1 (en) * 2018-09-05 2020-03-11 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases
ES2971892T3 (es) * 2018-12-14 2024-06-10 Chia Tai Tianqing Pharmaceutical Group Co Ltd Formas cristalinas del inhibidor de Syk sal hidrocloruro de 5-fluoro-1-metil-3-[[5-[4-(3-oxetanil)-1-piperazinil]-2-piridinil]amino]-6-(1H-pirazol-3-il)-2(1H)-quinolinona (1:1)
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
SI4175719T1 (sl) 2020-07-02 2025-07-31 Incyte Corporation Triciklične sečninske spojine kot zaviralci jak2 v617f
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
US11958861B2 (en) 2021-02-25 2024-04-16 Incyte Corporation Spirocyclic lactams as JAK2 V617F inhibitors
JP2024543981A (ja) * 2021-12-01 2024-11-26 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 炎症性疾患の処置に使用するためのｉｒａｐアミノペプチダーゼ阻害剤の使用
US12084430B2 (en) 2022-03-17 2024-09-10 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2472066A (en) * 1949-06-07 Z-arylamino-x-halogenoqtjinolines
DE537104C (de) * 1926-05-04 1933-03-17 Chem Ind Basel Verfahren zur Darstellung von substituierten Chinolincarbonsaeureamiden
DE858698C (de) * 1951-02-09 1952-12-08 Basf Ag Verfahren zur Herstellung von Pyridin- und Chinolinderivaten
GB811957A (en) * 1956-03-01 1959-04-15 Geigy Ag J R Improvements relating to 2-hydroxy-4-arylamino-quinolines
FR6103M (enExample) * 1967-02-22 1968-06-10
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
FR2538388B1 (fr) * 1982-12-24 1985-06-21 Pharmuka Lab Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments
JPH05310702A (ja) * 1992-05-06 1993-11-22 Kyowa Hakko Kogyo Co Ltd 抗炎症剤、免疫調整剤およびキノリン−２，４−ジカルボン酸ジアミド誘導体
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
US6197788B1 (en) * 1997-11-26 2001-03-06 Vernalis Research Limited (−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders
AU3386700A (en) * 1999-03-02 2000-09-21 Merck & Co., Inc. 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
EP1377554A1 (en) * 1999-06-16 2004-01-07 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
US6593324B2 (en) * 2000-03-01 2003-07-15 Orion Corporation Dervatives of quinoline as alpha-2 antagonists
DE60114227T2 (de) * 2000-08-16 2006-04-20 Neurogen Corp., Branford 2,4-substituierte pyridinderivate
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
CN100376557C (zh) * 2001-05-21 2008-03-26 霍夫曼-拉罗奇有限公司 作为神经肽y受体的配体的喹啉衍生物
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
SE0102858D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds
MXPA05000081A (es) * 2002-06-27 2005-04-11 Schering Ag Quinolinas sustituidas antagonistas del receptor ccr5.
EP1631810A4 (en) * 2003-03-10 2008-11-05 Schering Corp Ligand ANALYSIS

Also Published As

Publication number Publication date
JP2006519846A (ja) 2006-08-31
WO2004080463A1 (en) 2004-09-23
MXPA05009722A (es) 2006-03-09
EP1601357A4 (en) 2007-10-03
EP1601357A1 (en) 2005-12-07

Similar Documents

Publication Publication Date Title
CA2518398A1 (en) Heterocyclic kinase inhibitors: methods of use and synthesis
JP2006519846A5 (enExample)
US7442698B2 (en) Substituted heterocyclic compounds and methods of use
US6316444B1 (en) SRC kinase inhibitor compounds
TWI527800B (zh) 作為聚（二磷酸腺苷酸－核醣）聚合酶（ｐａｒｐ）之抑制劑之１－（芳基甲基）喹唑啉－２，４（１ｈ，３ｈ）－二酮及其應用
AU2005332339B2 (en) Furanopyridine derivatives as ACK1 and Lck modulators
JP2003503351A (ja) Ｓｒｃキナーゼ阻害化合物
EP2150546A2 (en) Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase
BG62089B1 (bg) Инхибитори на hiv реверсивна транскриптаза
BG65106B1 (bg) Заместени 2-арил-3-(хетероарил)-имидазо[1,2-а]пиримидини, лекарствени средства, които ги съдържат, използването им и метод за тяхното получаване
KR20150011838A (ko) 탄키라아제 억제제로서의 피롤로피라존
WO2008125835A1 (en) 2-morpholin-4-yl-pyrimidines as pi3k inhibitors
JP2003501429A (ja) ベンゾチアジノンおよびベンゾオキサジノン化合物
MXPA03002294A (es) Compuestos de pirazol utiles como inhibidores de proteina cinasa.
EP3889134A1 (en) Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof
JP2003525295A (ja) １，５−二置換−３，４−ジヒドロ−１ｈ−ピリミド［４，５−ｄ］ピリミジン−２−オン化合物およびｃｓｂｐ／ｐ３８キナーゼ介在疾患の治療におけるその使用
TWI601724B (zh) 咪唑並喹啉類衍生物及其可藥用鹽、其製備方法及其在醫藥上的應用
KR20170140370A (ko) Jak 억제제
KR20140021629A (ko) 단백질 키나제 저해제
JP7602630B2 (ja) アリールリン酸化物化合物およびその使用
JP2010529129A (ja) キナーゼ阻害剤化合物
EA013863B1 (ru) 2,5- и 2,6-дизамещенные аналоги бензазола, полезные в качестве ингибиторов протеинкиназ
US20080119515A1 (en) Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis
WO2005042518A2 (en) Substituted heterocyclic compounds and methods of use
CA2117062A1 (en) New tricyclic thiazole and oxazole derivatives and pharmaceutical agents containing them

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead